Estradiol enantate and cyproterone depot for MTF HRT: what the evidence says

What's this video probably claiming?

Based on the caption and hashtags, this creator is likely reviewing two injectable medications used in feminizing hormone therapy: Pampafresh (estradiol enantate) and Androcur Depot (cyproterone acetate depot injection). These are popular in Latin American trans healthcare communities, where injectable estrogens are more accessible than in North America. The creator is almost certainly describing their personal injection experience, frequency, how the drugs make them feel, and possibly comparing them to oral or patch-based HRT. Given the show link, there's likely a product recommendation angle. The review format suggests they're positioning these injectables as preferable to other delivery methods, possibly claiming smoother hormone levels, better feminization, or reduced side effects compared to oral estradiol or estradiol valerate. These are common and partially legitimate talking points, but the devil is always in the pharmacokinetic details.

What does the science actually show?

Estradiol enantate is a long-acting injectable ester with a half-life of roughly 4-7 days, producing relatively stable serum estradiol levels compared to oral administration, which causes significant first-pass hepatic metabolism and peak-and-trough fluctuations. A 2019 review by Weinand and Safer in the Journal of Clinical Endocrinology and Metabolism confirmed that parenteral estradiol reduces hepatic clotting factor synthesis compared to oral routes, theoretically lowering thrombosis risk. Cyproterone acetate, the active compound in Androcur, is a potent anti-androgen and progestogen. Studies including Toorians et al. (2003, Journal of Clinical Endocrinology and Metabolism) found cyproterone effectively suppresses testosterone to female reference ranges in most trans women within 3-6 months. However, cyproterone carries a dose-dependent risk of meningioma, with Aly et al.'s analysis of French pharmacovigilance data (2020) showing elevated risk at cumulative doses above 3,500 mg. Depot formulations deliver higher single doses, which complicates this risk picture considerably.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok HRT content and clinical reality is the near-total absence of risk communication. Creators reviewing injectable HRT rarely mention that cyproterone acetate is banned in the United States and Canada precisely because of meningioma data. They also tend to present smooth hormone curves as a guaranteed outcome of injectables without acknowledging that injection technique, site rotation, and individual pharmacokinetics create real variability. Another common claim, that estradiol enantate is clearly superior to estradiol valerate for feminization outcomes, is not supported by head-to-head clinical trial data. Most comparative evidence is observational or based on pharmacokinetic modeling, not controlled feminization outcome studies. There's also a tendency in these communities to frame self-administered depot injections as equivalent to clinic-supervised HRT, which glosses over the monitoring that responsible prescribers require, including prolactin checks, liver enzymes, and MRI surveillance for long-term cyproterone users.

What should you actually know?

If you're a trans woman considering injectable HRT, the pharmacology is genuinely interesting and the preference for parenterals over oral estrogens has some clinical backing. But cyproterone acetate depot is not a benign anti-androgen. The meningioma signal is real enough that the European Medicines Agency issued a 2020 label update requiring MRI surveillance for patients on cumulative doses above 160 mg total, let alone depot regimens. Anyone on long-term cyproterone should have prolactin monitored regularly because hyperprolactinemia is a known adverse effect. Estradiol enantate itself has a reasonable safety profile when levels are monitored, but target ranges matter: most guidelines, including WPATH Standards of Care Version 8 (2022), recommend maintaining serum estradiol between 100-200 pg/mL for feminizing therapy, not chasing supraphysiological peaks. A TikTok review, however well-intentioned, cannot substitute for baseline labs, ongoing monitoring, and a prescriber who actually knows your history.